The report details significant collaborative arrangements and related party transactions for the fiscal year ending December 31, 2025. Key financial movements include a substantial increase in deferred other income and revenue remaining from performance obligations, alongside significant losses on investments in preferred stocks and SAFEs.

Ginkgo Bioworks reported a challenging third quarter in 2025, with total revenue decreasing to $38.837 million from $89.046 million in the prior year. The company experienced a net loss of $80.755 million, an increase from $56.403 million in Q3 2024. Cash and cash equivalents saw a substantial decline, ending the quarter at $111.065 million compared to $561.572 million at the end of 2024.

Ginkgo Bioworks demonstrated strong commercial traction in Q2 2025, driven by growing demand for its AI in biology platform, securing new government contracts, and expanding biopharma service offerings. The company also successfully achieved its $250 million annualized cost-reduction goal three months ahead of schedule, reflecting rigorous financial discipline.

Ginkgo Bioworks reported a net loss of $90.957 million in Q1 2025, an improvement from the $165.911 million net loss in Q1 2024. Total revenue increased to $48.318 million, driven by a significant increase in Cell Engineering revenue.

Ginkgo Bioworks reported a total revenue of $44 million for Q4 2024, an increase from $35 million in the comparable prior year period. The company significantly reduced its GAAP net loss to $(108) million from $(212) million and improved Adjusted EBITDA to $(57) million from $(101) million in the comparable prior year period, driven by increased revenue and decreased operating expenses. Cash flow also improved significantly.

Ginkgo Bioworks reported a 61% increase in total revenue to $89 million for Q3 2024, which includes $45 million from a non-cash deferred revenue release. Excluding this impact, revenue decreased by 21%. The company signed new deals with Novo Nordisk and achieved a major research milestone with Merck. They also made progress on cost reductions and are consolidating their real estate footprint.

Ginkgo Bioworks reported a decrease in total revenue to $38 million for Q1 2024, down from $81 million in the comparable prior year period. The company is implementing initiatives to reduce operating expenses by $200 million by mid-2025 and targeting adjusted EBITDA breakeven by the end of 2026, supported by a cash balance of $840 million.

Ginkgo Bioworks reported Q4 2023 total revenue of $35 million, a decrease of 65% compared to the prior year, driven by reduced Biosecurity revenue and lower Cell Engineering downstream value share. The company's loss from operations was $(178) million. Year-end cash balance was nearly $950 million.

Ginkgo Bioworks reported a 17% decrease in total revenue to $55 million, primarily due to the expected ramp down of K-12 testing in the Biosecurity segment. However, Cell Engineering revenue increased by 51% to $37 million. The company added 21 new Cell Programs and ended the quarter with over $1.0 billion in cash and cash equivalents.

Ginkgo Bioworks reported a total revenue of $81 million, a 44% decrease compared to the prior year, driven by the expected ramp down of K-12 testing in the Biosecurity segment. However, Cell Engineering revenue increased slightly, and the company added 21 new Cell Programs to its Foundry platform. The company ended the quarter with approximately $1.1 billion in cash and cash equivalents.

Ginkgo Bioworks reported a total revenue of $81 million for Q1 2023, a 52% decrease compared to the previous year. This decline was primarily due to the expected reduction in K-12 testing within the Biosecurity business. However, Cell Engineering revenue increased by 59% year-over-year, reaching $34 million. The company's cash and cash equivalents balance remained strong at approximately $1.2 billion.

Ginkgo Bioworks reported a decrease in total revenue for Q4 2022, primarily due to an expected reduction in K-12 COVID-19 testing services. However, Foundry revenue increased, and the company added 20 new Cell Programs. The company's cash balance remains strong, providing flexibility for future growth.